Zura Bio Limited (ZURA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Robert Lisicki | CEO & Director | 854.21k | -- | 1967 |
| Dr. Someit Sidhu M.D. | Founder & Director | 1.01M | -- | 1990 |
| Ms. Kimberly Ann Davis J.D. | COO, Chief Legal Officer & Corporate Secretary | 653.84k | -- | 1968 |
| Dr. Kiran Nistala MBBS, Ph.D. | Chief Medical Officer & Head of Development | 597.41k | -- | 1973 |
| Mr. Verender S. Badial | Chief Financial Officer | 462k | -- | 1973 |
| Dr. Gary Whale Ph.D. | Chief Technology Officer | -- | -- | 1974 |
| Ms. Theresa Lowry | Chief Human Resources Officer | -- | -- | 1974 |
Zura Bio Limited
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 30
Description
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Corporate Governance
Upcoming Events
August 13, 2025 at 10:30 AM UTC - August 17, 2025 at 10:30 AM UTC
Zura Bio Limited Earnings Date